Your search
Results 52 resources
-
Abstract. These updated guidelines replace the previous management guidelines published in 2001. The guidelines are intended for use by health care providers w
-
To support evidence-based clinical & shared decision-making during the 2026-2027 respiratory tract infection season, IDSA developed rapid guidelines for the use of U.S-licensed vaccine against COVID-19, Influenza, and RSV in adult and pediatric patients who are immunocompromised. Immunocompromised patients are defined as individuals who have impaired immune systems either due to their underlying disease (e.g. HIV, malignancy) or due to the medications they must take (e.g. solid organ...
-
IDSA Guidelines on Antigen Testing for the Diagnosis of COVID-19 now available. These evidence-based rapid guidelines will address pressing clinical questions related to optimal use of SARS-CoV-2 Antigen tests in both medical and non-medical settings.
-
This is Part 1 of new consensus statements by IDSA/ESCMID on Staphylococcus aureus Bacteremia: Risk Stratification, Diagnostic Evaluation, and Management of Adults and Children.
-
SARS-CoV-2 is a highly transmissible virus that can infect health care personnel and patients in health care settings. Specific care activities, in particular aerosol-generating procedures, may have a higher risk of transmission. The rapid emergence and global spread of SARS-CoV-2 has created significant challenges in health care facilities, particularly with severe shortages of personal protective equipment (PPE) used to protect health care personnel (HCP). Summarized here are the...
-
Serologic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now widely available. IDSA has developed recommendations related to the use of SARS-CoV-2 serologic testing in clinical practice and public health.
-
Direct detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acids in respiratory tract specimens informs patient, healthcare institution, and public health level decision-making. IDSA has developed an evidence-based diagnostic guideline to assists clinicians, clinical laboratorians, patients and policymakers in decisions related to the optimal use of SARS-CoV-2 nucleic acid amplification tests.
-
2026 AMR GuidanceTamma, P. D., Bonomo, Robert A., Heil, Emily L., … Mathers, Amy J. - 2026, July 30
This updated IDSA AMR Guidance document provides treatment suggestions for infections caused by extended-spectrum β-lactamase–producing Enterobacterales (ESBL-E), AmpC β-lactamase–producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa with difficult-to-treat resistance (DTR P. aeruginosa), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia.
Filter by our tag
GUIDELINES
- IDSA Guidelines
- AASLD Guidelines (2)
- AHA Guidelines (1)
- ESCMID Guidelines (2)
- SCCM Guidelines (2)
CORE CURRICULUM
- INTRO MALIGNANT HEME, HSCT, CAR-T (1)
-
ORGANISMS
(7)
- Bacteria (2)
- Fungi (3)
- Mycobacteria (1)
- Viruses (1)
- SYNDROMES (3)
ORGANISMS
-
BACTERIA
(9)
- C. difficile (1)
- MDR GNR (2)
- MRSA (2)
- Non-tuberculous Mycobacteria (1)
- Tuberculosis (3)
-
FUNGI
(11)
- Aspergillus (2)
- Candida (1)
- Cryptococcus (2)
- Dimorphic mycoses (6)
-
VIRUSES
(9)
- CMV (1)
-
COVID-19
(5)
- Diagnosis (3)
- GUIDELINES (5)
- Infection Prevention (1)
- Treatments (1)
- Hepatitis B (2)
- Hepatitis C (1)
- Influenza (1)
- Respiratory Viruses (1)
DRUGS AND THERAPIES
- Antibiotics (1)
- Antifungals (1)
- Phage therapy (1)
PREVENTION
- Vaccination (1)
SYNDROMES AND CONDITIONS
- Endovascular infections (2)
- Osteomyelitis and Diabetic Foot Infection (2)
- Pneumonia (2)
- UTI (3)
SOLID ORGANS AND MCSS
- Liver (1)
HEME-ONC AND CELLULAR THERAPIES
- BMT Basics (1)
- Heme-onc prophylaxis (1)
- Neutropenia (3)